Over the past 12 months pharmaceutical market demonstrates steady growth, which means that the incomes of drug manufacturers are growing steadily. The pharmaceutical industry has traditionally been considered one of the most profitable sectors of the economy.
However, entering this market is not easy at all, with major manufacturers investing billions of dollars in drug development, patenting and marketing. Today we present rating of the largest pharmaceutical companies, which represents the world's major players in the pharmaceutical industry.
The company was founded in 1863 in Germany. Bayer manufactures pharmaceuticals for humans and animals, nutritional supplements and agrochemical fertilizers.
9. Merck & Co
The headquarters of this pharmaceutical company is located in New Jersey, USA. Merck & Co. was founded in 1891 as a subsidiary of the German company Merck KGaA. During the war, the division was confiscated by the American government and turned into an independent company.
8. Abbott Laboratories
The American pharmaceutical company was founded in 1888. And in 2010, Abbott Laboratories' turnover exceeded $ 35 billion. The company employs over 91 thousand people.
The Swedish-British company was founded in 1999 through the merger of the Swedish Astra AB with the British Zeneca. AstraZeneca's turnover is approximately $ 25 billion. Today the pharmaceutical company employs over 50 thousand people.
The French pharmaceutical company produces medicines for various diseases, vaccines, cancer drugs, etc. At the same time, Sanofi is an employer for 112 thousand people.
The Swiss company was founded in 1996. Subsidiary brands of Novartis are the contact lens manufacturers Alcon and Ciba Vision, as well as the pharmaceutical company Sandoz.
The British pharmaceutical company has offices in 114 countries. GSK has 24 research laboratories. The company employs 99 thousand people.
The Swiss holding is actively working in the market of innovative drugs. F. Hoffmann-La Roche owns three subsidiaries working in the field of biotechnology. The holding is an employer for 85 thousand people.
The American company was founded in 1849 by two cousins who were immigrants from Germany. The company's turnover today exceeds $ 51 billion. Pfizer employs 78,000 people.
The largest Russian pharmaceutical companies earned from 15 billion rubles (PJSC Pharmstandard) to 182 billion rubles (AO NPK Katren) in annual revenue at the end of 2015.
The last two years of 2015 and 2016, the Russian pharmaceutical industry has shown significant growth - more than 20% in 2016, according to the statement of the Minister of Industry and Trade of the Russian Federation, Denis Manturov.
At a briefing held at the Russian Ministry of Industry and Trade, Deputy Minister Sergei Tsyb said that the best proof of the growth of the domestic pharmaceutical industry is that American pharmaceutical giants are outraged: it is difficult for them to break into Russian market, since they are being ousted by large pharmaceutical companies in Russia. We analyzed and prepared the Top 7 largest Russian pharmaceutical holdings by revenue in 2015.
Pharmstandard
Legal address: Moscow
Registration date: 1996 year
Founders: Minin Alexander Nikolaevich, Kuznetsov Igor Gennadievich.
General manager: Igor Kuznetsov
- Authorized capital: RUB 1,000,012.86
- Fixed assets: 153 955 thousand rubles
- Revenue: 21,191,811
- Accounts receivable: 2 667 522 thousand rubles
- Accounts payable: 6,961,274 thousand rubles.
- Net profit: 1,042,833 thousand rubles
- Net assets: 2 646 595 thousand rubles
- INN - 7731241639
http://www.euro-service.ru/
Sia International
Joint-stock company "Sia International LTD" is engaged in the sale of drugs and medical products to pharmacies and medical institutions.
It has warehouse complexes in Moscow and more than 35 cities in Russia. Their total area is more than 200 thousand square meters.
Legal address: Moscow city
Registration date: 1995 year
Founders: JSC "Rink", Rudinsky Igor Feliksovich.
General manager: Demkin Alexander Yurievich
- Authorized capital: 20,000,000 rubles
- Fixed assets: 5 624 687 thousand rubles.
- Revenue: 59 438 184 thousand rubles
- Accounts receivable: 13,597,841 thousand rubles.
- Accounts payable: 20 209 002 thousand rubles.
- Net profit: -3 111 114 thousand rubles
- Net assets: 2,908,224 thousand rubles
- INN - 7714030099
Sources: official website: http://siamed.ru/, extract from the Unified State Register of Legal Entities, Rosstat (data financial statements according to RAS for 2015).
R-Pharm
R-Pharm Joint Stock Company specializes in high-tech medicines. The company is currently working towards large-scale investment projects.
Creates a production base as part of the state strategy for the development of the Russian pharmaceutical industry until 2020.
Legal address: Moscow
Registration date: year 2001
Founders: Repik Alexey Evgenievich
General manager: Vasily Ignatiev
- Authorized capital: 28,400 rubles.
- Fixed assets: 2 119 636 thousand rubles
- Revenue: 62,204,014 thousand rubles
- Accounts receivable: 13 435 674 thousand rubles.
- Accounts payable: 30,682,362 thousand rubles
- Net profit: 8 608 010 thousand rubles.
- Net assets: 24,205,818 thousand rubles
- INN - 7726311464
Sources of information: official website: http://r-pharm.com, extract from the Unified State Register of Legal Entities, Rosstat (financial statements under RAS for 2015).
Growth
Closed joint-stock company"Growth". In total, the pharmaceutical group "Rosta" includes 4 companies: "Rosta" (engaged in the distribution of medicines), "Rosta-marketing" (trade marketing), "Raduga Production" (a plant for the production of solid medicines), United Pharmacy Network, which includes the companies "Raduga", "First Aid", "Ladushka".
Legal address: Moscow region, city of Podolsk
Registration date: 2002 year
Founders: Joint-stock company PJSC "Tampo", Mirilashvili Mikhail Mikhailovich, Panikashvili David Isaakovich, Zeitlin Oleg Yakovlevich, Strepetov Vadim Valentinovich, Shepel Boris Albertovich, Semenyuk Alexander Vasilyevich, Konev Oleg Yurievich.
The president: Panikashvili David Isaakovich
- Authorized capital: 1,000,000 rubles
- Fixed assets: 621 356 thousand rubles
- Revenue:63 384 563 thousand rubles
- Accounts receivable: 18,293,282 thousand rubles.
- Accounts payable: 35 244 901 thousand rubles
- Net profit: 415,314 thousand rubles
- Net assets: 1,755,002 thousand rubles.
- INN - 7726320638
Sources: official website: http://www.rostagroup.ru/, extract from the Unified State Register of Legal Entities, Rosstat (financial statements under RAS for 2015).
Protek
Closed joint-stock company firm "Center of implementation" Protek ". The group of companies "Protek" is engaged in the production, distribution and retail sale through pharmacy networks of medicines.
The production and technological facilities of the holding comply with GMP standards.
Legal address: Moscow city
Registration date: 1994 year
Founders: OJSC "Protek"
General manager: Dmitry Pogrebinsky
- Authorized capital: 40,000,000 rubles
- Fixed assets: 1,082,865 thousand rubles.
- Revenue: 166 578 310 thousand rubles
- Accounts receivable: 32,742,113 thousand rubles.
- Accounts payable: 69,059,867 thousand rubles
- Net profit: 5,419,719 rubles.
- Net assets: 8 094 159 rubles
- INN - 7724053916
Sources of information: the official website of the company: http://www.protek-group.ru, an extract from the Unified State Register of Legal Entities, Rosstat (data of financial statements under RAS for 2015).
Quatrain
Geography of Katren's work covers 85 constituent entities of the Russian Federation, delivers more than 18 thousand types of pharmaceutical products.
Legal address: city Novosibirsk
Registration date: 1993 year
Founders: Konobeev Leonid Valentinovich, Spiridonov Vladimir Nikolaevich
General manager: Konobeev Leonid Valentinovich
- Authorized capital: 1 billion 500 million rubles
- Fixed assets: 6,752,880 thousand rubles
- Revenue: 182 301 551 thousand rubles
- Accounts receivable: 30,155,368 thousand rubles.
- Accounts payable: 65 656 588 thousand rubles
- Net profit: 5,790,742 thousand rubles
- Net assets: 11,103,940 thousand rubles.
- INN - 5408130693
Sources: official website: http://katren.ru, extract from the Unified State Register of Legal Entities, Rosstat (data from RAS financial statements for 2015).
It is no exaggeration to say that providing citizens with medicines and drugs is an important component of the national security of the state. And pharmaceutical production is the most important socially significant sector of the economy.
Government support
To date social significance products such as pharmaceuticals, the production of which is established on the territory of our country, has reached such a level that the government is forced to pay serious attention to projects involving the development of this industry. It should be noted that for last years a number of policy documents have been adopted, contributing to the organization and development of production, including pharmaceutical substances, but the situation in this area still does not inspire optimism, and here is why.
Important features of the industry
Pharmaceutical production has its own characteristics. They are presented:
- high science intensity of products;
- the considerable duration of the process of developing new medicinal components, as well as the corresponding drugs;
- long life cycle drugs, including all stages - development, production and sale of products;
- the nature, as well as the duration of the production cycle required for the release finished products;
- a wide variety of species technological processes that are used in such areas as the production of pharmaceutical substances;
- a wide variety of raw materials and materials, as well as equipment used in the production cycle;
- multistage technological processes.
Investment
From the point of view of a potential investor, pharmaceutical production has a number of distinctive features. And the main negative points, which are worth paying attention to, look like this:
- Higher investment attractiveness of the production of finished products, that is, medicinal products, in comparison with the production of medicinal substances. This trend has developed under the influence of current economic conditions. This fact can be explained by the high material and energy intensity of the production of standardized semi-finished products, which led to a decrease in the profitability of their production, and sometimes to the loss of such production.
- The increase in the cost of material resources in Lately, which also caused a significant increase in the cost of substances produced on the territory of our country. The consequence of this is on them to a level exceeding the world one. These trends have led to the fact that the pharmaceutical industry has become unable to offer competitive products.
- Providing foreign manufacturers easy access to the pharmaceutical market of our country. This created colossal competition for each domestic manufacturer, which in most cases is unable to resist the active expansion of inexpensive substances of low quality on the domestic market.
The main trends in the pharmaceutical market
According to some estimates, the volume of the pharmaceutical market in recent years in our country reaches 1 trillion rubles. At the same time, domestic medicines in the total volume of sold products of this type make up only about 25%, in monetary terms, and about 60% in kind.
Sharp questions
Today, one of the most pressing issues that worries people interested in the development of domestic pharmaceutical production is the origin of standardized semi-finished products, which are the basis for the production of finished pharmaceuticals on the territory of our state. Unfortunately, the experts' conclusions do not inspire optimism in domestic producers. Pharmaceutical production of medicinal components in our country is practically not developed.
Import of pharmaceutical substances
As for imports, in recent years there has been a situation where about 80% of the volume of imported pharmaceutical substances in monetary terms is occupied by Germany, France, Italy and China.
It is noteworthy that, when considering the natural expression of import volumes, completely different figures are obtained. So, its largest share today is China - more than 70% of the total. Considering the ratio of specific shares calculated by natural and cost indicators, one can come to the conclusion that the substances produced in the named country are characterized by a much lower price in comparison with similar products from other countries.
What is imported
The import includes mainly the components of very long-known drugs, represented by acetylsalicylic acid, paracetamol, sodium metamizole, metformin, ascorbic acid and others that are in demand among the population, mainly due to their low cost, means.
He says that the share of products produced at domestic enterprises is characterized by a negligible figure, 8-9% of the total volume of the pharmaceutical market.
conclusions
Probably, the above facts make it possible to assert the obviousness of the need to restore production volumes of the products under consideration. The technology of pharmaceutical production of substances must be restored and applied in full. The development of this area is necessary, first of all, in order to ensure the national security of the state.
Such statements are not empty words at all. Many manufacturers are faced with the fact of providing the domestic economy with substances from foreign suppliers by the residual principle. And this cannot but cause concern.
As in any field, there is a rating of the best drug manufacturers among pharmaceutical companies in Russia on the service market. More than 950 drug manufacturers operate in Russia. A third of the pharmacy market is occupied by companies that are located at the very top of the rating of the best manufacturers. The value of drug sales determines the place of a pharmaceutical company in the ranking of the strongest.
Novartis
The drug manufacturing company Novartis is in the most honorable place in the ranking. Novartis is the second largest in the world and produces drugs such as Linex, Amoxiclav, Otrivin. This company is Swiss.
Sanofi-aventis
Bayer
The third place was taken by Bayer. Its head office is located in Germany. Branches of the corporation operate in almost every country in the world. Bayer is active in drug innovation. The company is dominated by natural science, and Bayer collaborates with doctors, veterinarians and farmers to understand the most difficult challenges of our time.
Takeda
Pharmaceutical company Takeda was ranked fourth in the ranking of the strongest manufacturers in the pharmacy market. Takeda is a Japanese company with offices in more than seventy countries around the world. The global industry leader focuses on diseases of the central nervous system, metabolic diseases, oncology, cardiovascular diseases, and also produces vaccines.
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd is headquartered in Israel. This manufacturing company is known for the production of generic drugs. Teva products are distributed in 120 countries. 44 factories produce pharmaceuticals, the names of which are about 1480 items. Teva Pharmaceutical Industries Ltd has been on the market for over a century. She was originally based in Jerusalem. In addition to generic drugs, the company develops innovative drugs in a variety of areas.
The corporations ranked in the top five pharmaceutical manufacturing firms are the most active and successful. They are constantly busy developing new drugs that meet the requirements of mankind. These companies never stand still. They are expanding, improving the quality of medicines, and are reliable suppliers of pharmaceutical products to the market.
